These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 20969483)

  • 1. Implications of HIV PrEP trials results.
    Veronese F; Anton P; Fletcher CV; DeGruttola V; McGowan I; Becker S; Zwerski S; Burns D;
    AIDS Res Hum Retroviruses; 2011 Jan; 27(1):81-90. PubMed ID: 20969483
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral preexposure anti-HIV prophylaxis for high-risk U.S. populations: current considerations in light of new findings.
    Myers GM; Mayer KH
    AIDS Patient Care STDS; 2011 Feb; 25(2):63-71. PubMed ID: 21284497
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Daily oral tenofovir and emtricitabine-tenofovir preexposure prophylaxis reduces herpes simplex virus type 2 acquisition among heterosexual HIV-1-uninfected men and women: a subgroup analysis of a randomized trial.
    Celum C; Morrow RA; Donnell D; Hong T; Hendrix CW; Thomas KK; Fife KH; Nakku-Joloba E; Mujugira A; Baeten JM;
    Ann Intern Med; 2014 Jul; 161(1):11-9. PubMed ID: 24979446
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiretroviral pre-exposure prophylaxis (PrEP) for preventing HIV in high-risk individuals.
    Okwundu CI; Uthman OA; Okoromah CA
    Cochrane Database Syst Rev; 2012 Jul; (7):CD007189. PubMed ID: 22786505
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Study design considerations for evaluating efficacy of systemic preexposure prophylaxis interventions.
    Donnell D; Hughes JP; Wang L; Chen YQ; Fleming TR
    J Acquir Immune Defic Syndr; 2013 Jul; 63 Suppl 2(0 2):S130-4. PubMed ID: 23764624
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Update to Interim Guidance for Preexposure Prophylaxis (PrEP) for the Prevention of HIV Infection: PrEP for injecting drug users.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2013 Jun; 62(23):463-5. PubMed ID: 23760186
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk of drug resistance among persons acquiring HIV within a randomized clinical trial of single- or dual-agent preexposure prophylaxis.
    Lehman DA; Baeten JM; McCoy CO; Weis JF; Peterson D; Mbara G; Donnell D; Thomas KK; Hendrix CW; Marzinke MA; Frenkel L; Ndase P; Mugo NR; Celum C; Overbaugh J; Matsen FA;
    J Infect Dis; 2015 Apr; 211(8):1211-8. PubMed ID: 25587020
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systemic preexposure prophylaxis for HIV: translating clinical data to clinical practice.
    Li J; Dufrene SL; Okulicz JF
    Ann Pharmacother; 2014 Apr; 48(4):507-18. PubMed ID: 24473492
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changes in glomerular kidney function among HIV-1-uninfected men and women receiving emtricitabine-tenofovir disoproxil fumarate preexposure prophylaxis: a randomized clinical trial.
    Mugwanya KK; Wyatt C; Celum C; Donnell D; Mugo NR; Tappero J; Kiarie J; Ronald A; Baeten JM;
    JAMA Intern Med; 2015 Feb; 175(2):246-54. PubMed ID: 25531343
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HIV preexposure prophylaxis in the United States: impact on lifetime infection risk, clinical outcomes, and cost-effectiveness.
    Paltiel AD; Freedberg KA; Scott CA; Schackman BR; Losina E; Wang B; Seage GR; Sloan CE; Sax PE; Walensky RP
    Clin Infect Dis; 2009 Mar; 48(6):806-15. PubMed ID: 19193111
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Unraveling the divergent results of pre-exposure prophylaxis trials for HIV prevention.
    van der Straten A; Van Damme L; Haberer JE; Bangsberg DR
    AIDS; 2012 Apr; 26(7):F13-9. PubMed ID: 22333749
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
    Grant RM; Lama JR; Anderson PL; McMahan V; Liu AY; Vargas L; Goicochea P; Casapía M; Guanira-Carranza JV; Ramirez-Cardich ME; Montoya-Herrera O; Fernández T; Veloso VG; Buchbinder SP; Chariyalertsak S; Schechter M; Bekker LG; Mayer KH; Kallás EG; Amico KR; Mulligan K; Bushman LR; Hance RJ; Ganoza C; Defechereux P; Postle B; Wang F; McConnell JJ; Zheng JH; Lee J; Rooney JF; Jaffe HS; Martinez AI; Burns DN; Glidden DV;
    N Engl J Med; 2010 Dec; 363(27):2587-99. PubMed ID: 21091279
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana.
    Thigpen MC; Kebaabetswe PM; Paxton LA; Smith DK; Rose CE; Segolodi TM; Henderson FL; Pathak SR; Soud FA; Chillag KL; Mutanhaurwa R; Chirwa LI; Kasonde M; Abebe D; Buliva E; Gvetadze RJ; Johnson S; Sukalac T; Thomas VT; Hart C; Johnson JA; Malotte CK; Hendrix CW; Brooks JT;
    N Engl J Med; 2012 Aug; 367(5):423-34. PubMed ID: 22784038
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preexposure prophylaxis for HIV prevention: where have we been and where are we going?
    Baeten JM; Haberer JE; Liu AY; Sista N
    J Acquir Immune Defic Syndr; 2013 Jul; 63 Suppl 2(0 2):S122-9. PubMed ID: 23764623
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term safety and efficacy of emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV-1 pre-exposure prophylaxis: week 96 results from a randomised, double-blind, placebo-controlled, phase 3 trial.
    Ogbuagu O; Ruane PJ; Podzamczer D; Salazar LC; Henry K; Asmuth DM; Wohl D; Gilson R; Shao Y; Ebrahimi R; Cox S; Kintu A; Carter C; Das M; Baeten JM; Brainard DM; Whitlock G; Brunetta JM; Kronborg G; Spinner CD;
    Lancet HIV; 2021 Jul; 8(7):e397-e407. PubMed ID: 34197772
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Should we fear resistance from tenofovir/emtricitabine preexposure prophylaxis?
    Parikh UM; Mellors JW
    Curr Opin HIV AIDS; 2016 Jan; 11(1):49-55. PubMed ID: 26633640
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pre-exposure chemoprophylaxis of HIV infection: quo vadis?
    Clercq ED
    Biochem Pharmacol; 2012 Mar; 83(5):567-73. PubMed ID: 22067069
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of preexposure prophylaxis for HIV-1 prevention among high-risk heterosexuals: subgroup analyses from a randomized trial.
    Murnane PM; Celum C; Mugo N; Campbell JD; Donnell D; Bukusi E; Mujugira A; Tappero J; Kahle EM; Thomas KK; Baeten JM;
    AIDS; 2013 Aug; 27(13):2155-60. PubMed ID: 24384592
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for the initial treatment of HIV infection.
    Cohen C; Elion R; Ruane P; Shamblaw D; DeJesus E; Rashbaum B; Chuck SL; Yale K; Liu HC; Warren DR; Ramanathan S; Kearney BP
    AIDS; 2011 Mar; 25(6):F7-12. PubMed ID: 21412057
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FDA treads carefully with PrEP.
    Holmes D
    Lancet Infect Dis; 2012 Jul; 12(7):515-6. PubMed ID: 22930826
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.